Association between the use of female hormones and the thrombin generation: Cross-sectional analysis of the Longitudinal Study on Adult Health (ELSA-Brasil)

Introduction: The thrombin generation assay (TGA) assesses the risk of developing thrombotic events. The aim of this study was to investigate the association between the use of oral contraceptives (OCs) and hormone therapy (HT) with the TGA and resistance to activated protein C (APC). Methods: Cross-sectional study with women from the Longitudinal Study of Adult Health (ELSA-Brasil). TGA was performed by the CAT method. Results: There was an association between all parameters of the TGA and the use of OCs and an association of lag time and peak time with the use of HT. Conclusion: The TGA allows us to assess the hypercoagulability status and may be useful in the management of female hormones users.

[1]  A. Tripodi.  Usefulness of Thrombin Generation , 2020, Hämostaseologie.

[2]  D. Glintborg,et al.  Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives. , 2015, Metabolism: clinical and experimental.

[3]  M. Callaghan,et al.  Hypercoagulability in adolescent girls on oral contraceptives‐global coagulation profile and estrogen receptor polymorphisms , 2015, American journal of hematology.

[4]  K. Brummel-Ziedins,et al.  Global assays of hemostasis , 2014, Current opinion in hematology.

[5]  J. Oldenburg,et al.  Impact of Hormone-Associated Resistance to Activated Protein C on the Thrombotic Potential of Oral Contraceptives: A Prospective Observational Study , 2014, PloS one.

[6]  J. Vandromme,et al.  Postmenopausal hormone therapy: risks and benefits , 2013, Nature Reviews Endocrinology.

[7]  F. Rosendaal,et al.  The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy , 2013, Journal of thrombosis and haemostasis : JTH.

[8]  Moyses Szklo,et al.  American Journal of Epidemiology Practice of Epidemiology Brazilian Longitudinal Study of Adult Health (elsa-brasil): Objectives and Design , 2022 .

[9]  E. Løkkegaard,et al.  Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9 , 2011, BMJ : British Medical Journal.

[10]  M. Alhenc-Gelas,et al.  Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens , 2011, Menopause.

[11]  M. Alhenc-Gelas,et al.  Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen , 2010, Menopause.

[12]  J. Rosing,et al.  Mechanisms of estrogen-induced venous thromboembolism. , 2010, Thrombosis research.

[13]  F R Rosendaal,et al.  The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study , 2009, BMJ : British Medical Journal.

[14]  Brasil. Ministério da Ciência,et al.  ELSA Brasil: maior estudo epidemiológico da América Latina , 2009 .

[15]  F. Rosendaal,et al.  Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor , 2008, Journal of thrombosis and haemostasis : JTH.

[16]  T. Baglin,et al.  Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study , 2007, British journal of haematology.

[17]  J. Heit.  Venous thromboembolism: disease burden, outcomes and risk factors , 2005, Journal of thrombosis and haemostasis : JTH.

[18]  M. Alhenc-Gelas,et al.  Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives , 2004, Journal of thrombosis and haemostasis : JTH.

[19]  Dominique Mottier,et al.  Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[20]  F. Rosendaal,et al.  Estrogens, progestogens and thrombosis , 2003, Journal of thrombosis and haemostasis : JTH.

[21]  P. Hannaford.  Cardiovascular Events Associated With Different Combined Oral Contraceptives , 2000, Drug safety.

[22]  M. Woodward,et al.  Thrombotic Variables and Risk of Idiopathic Venous Thromboembolism in Women Aged 45-64 Years , 2000, Thrombosis and Haemostasis.

[23]  P. Sandset,et al.  Hormone Replacement Therapy with Estradiol and Risk of Venous Thromboembolism , 1999, Thrombosis and Haemostasis.

[24]  H. Hemker,et al.  Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptives , 1997, British journal of haematology.

[25]  J. Castellsagué,et al.  Hormone replacement therapy and risk of venous thromboembolism: population based case-control study , 1997, BMJ.

[26]  J. Manson,et al.  Prospective study of exogenous hormones and risk of pulmonary embolism in women , 1996, The Lancet.

[27]  D. Girelli,et al.  Resistance to activated protein C in healthy women taking oral contraceptives , 1995, British journal of haematology.

[28]  P. Reitsma,et al.  Factor V Leiden (FVQ 506) is common in a Brazilian population , 1995, American journal of hematology.

[29]  W. Willett,et al.  Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study. , 1990, American journal of obstetrics and gynecology.

[30]  D. Mant,et al.  Oral contraceptives and venous thromboembolism: findings in a large prospective study. , 1986, British medical journal.

[31]  J. Dacie,et al.  A Simple Method of Studying the Generation of Thrombin in Recalcified Plasma , 1953, Journal of clinical pathology.

[32]  C. Lecut,et al.  [Is there a place for thrombin generation assay in routine clinical laboratory?]. , 2015, Annales de biologie clinique.

[33]  By,et al.  A THROMBIN GENERATION TEST THE APPLICATION IN HAEMOPHILIA AND THROMBOCYTOPENIA , 2022 .